Beam Therapeutics Inc (BEAM) — Capital Reinvestment Ratio

Latest as of December 2023: 0.03x

Beam Therapeutics Inc (BEAM) has a Capital Reinvestment Ratio of 0.03x as of December 2023, meaning it reinvests 0% of its operating cash flow ($135.07 Million) in capital expenditures ($3.59 Million). Check BEAM goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.03x
Capex / Operating Cash Flow

Operating Cash Flow

$135.07 Million
USD

Capital Expenditures

$3.59 Million
USD

Data as of

Dec 2023
Most recent filing

Beam Therapeutics Inc Capital Reinvestment Ratio (2022–2022)

This chart tracks Beam Therapeutics Inc's Capital Reinvestment Ratio across 1 annual periods. For the full cash flow conversion analysis, see Beam Therapeutics Inc (BEAM) cash flow conversion.

Annual Capital Reinvestment Ratio for Beam Therapeutics Inc (2022–2022)

Year-by-year Capital Reinvestment Ratio for Beam Therapeutics Inc from 2022 to 2022. See how much free cash does Beam Therapeutics Inc generate to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2022 2.17x $22.53 Million $48.95 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow